October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 20, 2025

Prevalent Oral HPV Infections Show Delayed Clearance, Study

3-country cohort measures oral HPV infection duration and clearance patterns in men.

Conexiant

October 20, 2025

Which Hair Loss Treatments Truly Deliver Results?

Researchers compare prescription and over-the-counter treatments for male hair loss to determine which best improve hair density.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 15, 2025

Medical Oddities: The Half-Hour Health Hack

Metabolic tweaks, sensory sweet spots, antiviral spice, and a soothing cup for the heart and more this week.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 14, 2025

Only 2% Screened: Closing the Male Gap

“Men would like to believe they’re indestructible, so a fracture doesn’t have the implication that it should."

KFF Health News

October 08, 2025

New Data Tie GLP-1 Therapies to GERD

"These potential risks should be weighed against the established clinical benefits of this drug class."

Conexiant